NMDA receptor antagonist 2 T40999

Product Introduction
Bioactivity


英文名: NMDA receptor antagonist 2

描述: NMDA receptor antagonist 2 is a highly potent and orally active NR2B subtype-selective antagonist of the N-methyl-D-aspartate (NMDA) receptor. It exhibits remarkable binding affinities, with an IC50 of 1.0 nM and a Ki value of 0.88 nM. This compound finds valuable application in scientific investigations focusing on neuropathic pain and Parkinson’s disease.

体外活性: NMDA receptor antagonist 2 leads to excellent potency at NR2B (K i =0.88 nM) and selectivity over hERG binding (IP=20000 nM). NMDA receptor antagonist 2 is evaluated in a functional assay measuring Ca 2+ flux in cells expressing recombinant NR1/NR2B receptors. Selectivity over the hERG-channel is evaluated in an MK-499-binding assay[1].NMDA receptor antagonist 2 is highly potent in a functional assay using cells expressing NR2B (IC 50 =1.0 nM) and remains equipotent in a binding assay using a sample of homogenized human temporal cortex (K i =0.81 nM). In an electrophysiology assay using NR2B receptors,?Compound 22?shows full blockade of ion flux with?K D =0.35 nM. Compound?22?also exhibits high levels of selectivity over NR2A (IC 50 =200 μM), hERG binding (IP=20 μM), α-adrenergic receptors based on Prazosin binding (IC 50 >100 μM),?and CYP P450s including CYP3A4, 2C9, and 2D6[1].

体内活性: In pharmacokinetic studies with higher species, NMDA receptor antagonist 2 shows excellent oral bioavailability (F=83%), half-life (T 1/2 =7.5 hours) and clearance (CL=3.6 mL/min/kg) in dog. And it exhibits moderate clearance (CL=12 mL/min/kg) and oral bioavailability (F=17%) in rhesus, the half-life (T 1/2 ) is 1.5 hours[1].In a rat pharmacokinetic study, NMDA receptor antagonist 2 shows oral bioavailability (F=23 %), half-life (T 1/2 =0.7 hours) and clearance (CL=24 mL/min/kg), the receptor occupancy ED 50 with oral administration is 4.8 mg/kg in rat[1].In the spinal nerve ligation model of neuropathic pain in rats, surgical ligation of two lumbar nerves in the spinal column induces a state of mechanical allodynia[1].NMDA receptor antagonist 2 (oral administration; 3-30 mg/kg) inhibits tactile allodynia in a dose-dependent manner after oral administration at 10 and 30 mg/kg. It produces an average improvement in the maximal possible effect of 15% (3 mg/kg), 41% (10 mg/kg), and 69% (30 mg/kg) compared to vehicle treated animals[1].NMDA receptor antagonist 2 (oral administration; 3-30 mg/kg) is efficacious in an acute rodent model of Parkinson’s disease. Haloperidol (HY-14538) is administered at a dose previously shown to elicit an acute cataleptic response in rats, compound 22 reduces catalepsy scores in a dose-dependent manner, producing average improvements of 34% (3 mg/kg), 86% (10 mg/kg), and 92% (30 mg/kg) when it compares to vehicle group[1].

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

关键字: NMDA receptor antagonist 2

NMDA receptor antagonist 2 T40999信息由TargetMol中国为您提供，如您想了解更多关于NMDA receptor antagonist 2 T40999报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途